Clinical Trials Directory

Trials / Sponsors / Sellas Life Sciences Group

Sellas Life Sciences Group

Industry · 7 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malign
Hematologic Malignancies
Phase 1 / Phase 22021-05-10
Active Not RecruitingGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Acute Myeloid Leukemia
Phase 32021-02-08
CompletedGalinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer
Phase 1 / Phase 22019-09-30
CompletedWT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Multiple Myeloma
Phase 1 / Phase 22013-04-01
CompletedWT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukem
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 22011-01-14
CompletedGalinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Phase 22010-12-21
AvailableExpanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Acute Myeloid Leukemia, Myelodysplastic Syndromes
——